ABOUT GTC BIOTHERAPEUTICS GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATrynŽ, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATrynŽ is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATrynŽ, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.
	Copyright 2006 GTC Biotherapeutics, All Rights Reserved